Lifeward (LFWD) said Thursday the US Food and Drug Administration has cleared ReWalk 7, the newest version of its personal exoskeleton device.
According to Lifeward, ReWalk 7 is a wearable device that allows users with spinal cord injury to stand and walk. The company said sales of ReWalk 7 in the US will start "as soon as the product is available."
Lifeward shares climbed by more than 70% in early trading on Thursday.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。